Kailera Therapeutics Inc

NEW
NAS:KLRA (USA)  
$ 17.34 +0.41 (+2.39%) 02:07 PM EST
At Loss
Market Cap:
$ 2.25B
Enterprise V:
$ 1.74B
Volume:
109.50K
Avg Vol (2M):
813.59K
Trade In:
Volume:
109.50K
At Loss
Avg Vol (2M):
813.59K

Business Description

Kailera Therapeutics Inc
NAICS : 541720 SIC : 8731
ISIN : US4829311020
Description
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
Name Current Vs Industry Vs History
Cash-To-Debt
50.78
Equity-to-Asset
-0.52
Debt-to-Equity
-0.03
Debt-to-EBITDA
-0.07
Interest Coverage
N/A
N/A
N/A
Piotroski F-Score
N/A/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank
-43.04

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI
30.36
9-Day RSI
32.38
14-Day RSI
35.87
3-1 Month Momentum %
-11.88

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
12.01
Quick Ratio
12.01
Cash Ratio
11.77

Dividend & Buy Back

Name Current Vs Industry Vs History
Name Current Vs Industry Vs History
ROA %
-34.21
ROIC %
-209.59
ROC (Joel Greenblatt) %
-2417.77
ROCE %
-38.74
Moat Score
2

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT
-10.98
EV-to-EBITDA
-11
EV-to-FCF
-14.22
Earnings Yield (Greenblatt) %
-9.11
FCF Yield %
-5.44

Financials

KLRA's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:KLRA

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017

Kailera Therapeutics Inc Executives

Details

GF Valueâ„¢

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -1.263
Beta -
3-Year Sharpe Ratio -
3-Year Sortino Ratio -
Volatility % -
14-Day RSI 35.87
14-Day ATR ($) 1.409678
20-Day SMA ($) 18.9215
12-1 Month Momentum % -
52-Week Range ($) 16.39 - 28.2271
Shares Outstanding (Mil) 129.57

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Kailera Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Kailera Therapeutics Inc Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Kailera Therapeutics Inc Frequently Asked Questions

What is Kailera Therapeutics Inc(KLRA)'s stock price today?
The current price of KLRA is $17.35. The 52 week high of KLRA is $28.23 and 52 week low is $16.39.
When is next earnings date of Kailera Therapeutics Inc(KLRA)?
The next earnings date of Kailera Therapeutics Inc(KLRA) is .
Does Kailera Therapeutics Inc(KLRA) pay dividends? If so, how much?
Kailera Therapeutics Inc(KLRA) does not pay dividend.

Guru Commentaries on NAS:KLRA

No articles.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1